Michael Braunagel

Title: Michael Braunagel: Innovator in Antibody Screening Technology

Introduction

Michael Braunagel is a notable inventor based in Mannheim, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of innovative methods for antibody screening. With a total of five patents to his name, Braunagel's work has had a substantial impact on research and development in this area.

Latest Patents

One of Braunagel's latest patents involves the construction of a phagemid that expresses an antibody fused to the coliphage pIII protein. This phagemid is designed to select specific antibodies from large gene libraries using small quantities of antigen. The antibody-pIII gene can be strongly repressed, allowing for the amplification of antibody libraries without the risk of deletion mutants predominating. After induction, large quantities of the fusion protein can be expressed, showcasing the efficiency and effectiveness of this innovative approach.

Career Highlights

Throughout his career, Michael Braunagel has worked with prestigious organizations, including the Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts. His work in these institutions has allowed him to advance his research and contribute to significant scientific advancements.

Collaborations

Braunagel has collaborated with notable colleagues such as Frank Breitling and Melvyn Little. These partnerships have further enriched his research and development efforts in the field of biotechnology.

Conclusion

Michael Braunagel's contributions to antibody screening technology exemplify the innovative spirit of modern inventors. His patents and collaborations reflect a commitment to advancing scientific knowledge and improving research methodologies.